BioSpace News Archive

Gravity Diagnostics is a CLIA certified, and CAP-accredited laboratory licensed in all 50 states that processed nearly 50% of the Commonwealth of Kentucky COVID-19 gold standard PCR tests during the pandemic.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [combined positive score (CPS ≥1)] as determined by a U.S. Food and Drug Administration (FDA)-approved test,

Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units to be distributed to one new employee with a grant date of July 1, 2021.

Novanta Inc. (Nasdaq:NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the 21st Annual CJS Securities New Ideas Summer Conference

Expanding application areas of genomics, and the availability of gene expression databases are key factors contributing to industry growth.

Increase in prevalence of cardiovascular diseases, and rising geriatric population are expected to drive market growth.

Growing geriatric population worldwide and surging prevalence of diabetes and cardiovascular diseases are projected to drive market growth.

NGM Biopharmaceuticals, Inc. announced that the company has entered into an amended and restated agreement with Merck, known as MSD outside the United States and Canada, to extend their ongoing collaboration through March 2024 but with a narrower scope.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced that it has been awarded funding from the United States Department of Defense to conduct a safety and immunogenicity study of M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.

Following a formal tender process, Nottingham University Hospitals (NUH) NHS Trust today announced the selection of Indica Labs to aid in full digitisation of the pathology workflow.